These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12408787)

  • 1. Hypertrophic Cardiomyopathy.
    Behr ER; McKenna WJ
    Curr Treat Options Cardiovasc Med; 2002 Dec; 4(6):443-453. PubMed ID: 12408787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypertrophic cardiomyopathy in children.
    Seggewiss H; Rigopoulos A
    Paediatr Drugs; 2003; 5(10):663-72. PubMed ID: 14510624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to Hypertrophic Cardiomyopathy.
    Autore C; Spirito P; Spirito P
    Curr Treat Options Cardiovasc Med; 2004 Dec; 6(6):489-498. PubMed ID: 15496266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.
    Elmariah S; Fifer MA
    Curr Treat Options Cardiovasc Med; 2012 Dec; 14(6):665-78. PubMed ID: 22956194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sudden cardiac death in familial hypertrophic cardiomyopathy. Identification of high-risk patients].
    Pellnitz C; Geier C; Perrot A; Dietz R; Osterziel KJ; Haverkamp W
    Dtsch Med Wochenschr; 2005 May; 130(18):1150-4. PubMed ID: 15856398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
    Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
    Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients.
    Fananapazir L; Tracy CM; Leon MB; Winkler JB; Cannon RO; Bonow RO; Maron BJ; Epstein SE
    Circulation; 1989 Nov; 80(5):1259-68. PubMed ID: 2805263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating a Structural Heart Disease Using a Non-structural Approach: Role of Cardiac Pacing in Hypertrophic Cardiomyopathy.
    Albano BB; Fadreguilan EC; Chua JM; Ho J; Medrano AB
    Cardiol Res; 2017 Feb; 8(1):20-25. PubMed ID: 28275421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine orthostatic LVOT gradient assessment in patients with basal septal hypertrophy and LVOT flow acceleration at rest: please stand up.
    Sinclair HC; Russhard P; Critoph CH; Steadman CD
    Echo Res Pract; 2019 Mar; 6(1):K1-K6. PubMed ID: 30668520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy.
    Fananapazir L; Cannon RO; Tripodi D; Panza JA
    Circulation; 1992 Jun; 85(6):2149-61. PubMed ID: 1350522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience.
    Kotkar KD; Said SM; Dearani JA; Schaff HV
    Ann Cardiothorac Surg; 2017 Jul; 6(4):329-336. PubMed ID: 28944173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes.
    Desai MY; Bhonsale A; Patel P; Naji P; Smedira NG; Thamilarasan M; Lytle BW; Lever HM
    JACC Cardiovasc Imaging; 2014 Jan; 7(1):26-36. PubMed ID: 24290569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy.
    Adabag AS; Casey SA; Kuskowski MA; Zenovich AG; Maron BJ
    J Am Coll Cardiol; 2005 Mar; 45(5):697-704. PubMed ID: 15734613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hypertrophic cardiomyopathy (HCM). Surgical versus drug therapy].
    Schulte HD; Gramsch-Zabel H; Schwartzkopff B; Gams E
    Z Kardiol; 1999 Mar; 88(3):163-72. PubMed ID: 10355066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.
    Lu DY; Pozios I; Haileselassie B; Ventoulis I; Liu H; Sorensen LL; Canepa M; Phillip S; Abraham MR; Abraham TP
    J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29478967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy.
    Behr ER; Elliott P; McKenna WJ
    Card Electrophysiol Rev; 2002 Dec; 6(4):482-6. PubMed ID: 12438832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy.
    Minami Y; Kajimoto K; Kawana M; Hagiwara N; Sherrid MV
    Int J Cardiol; 2010 May; 141(2):195-7. PubMed ID: 19097655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hypertrophic cardiomyopathy.
    Enriquez AD; Goldman ME
    Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy.
    Habib M; Hoss S; Bruchal-Garbicz B; Chan RH; Rakowski H; Williams L; Adler A
    Int J Cardiol; 2019 Dec; 297():75-82. PubMed ID: 31615649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.